Science

What’s the Buzz About? Fly Research Leads to Unexpected Epilepsy Discovery

Govind Kunduri, Ph.D., watched as a bright light illuminated a transparent tube full of mutant fruit flies. Then, as he prepared to collect data, something unexpected occurred: the flies began having seizures. The flies’ surprising behavior seemed epileptic, but Kunduri, a postdoctoral fellow in the Cancer and Developmental Biology Laboratory (CDBL), part of the Center for Cancer Research at NCI at Frederick, hadn’t intended to study epilepsy.

Tags: 

Two Investigators—One Aspiring and One Retiring—Share Discovery, Legacy, and Connection

Dennis Klinman, M.D., Ph.D., says science is like the surface of a sphere—there are thousands of possible connections between different points. It is fitting, therefore, that on the eve of his retirement, the senior investigator has helped a young scientist connect with her passion.

Tags: 

Inside the Scientific Arsenal: The High-Speed Racetrack That Can Make Proteins Explode

Ben Orsburn, Ph.D., stood in the middle of a 180-square-foot laboratory, speaking over the white noise that flooded the room. The source of the din—large, desk-sized objects called mass spectrometers—filled nearby rows of lab benches. Orsburn pointed to one along the periphery of the room, a white-and-black box with the words “Orbitrap Fusion” emblazoned on the front in small blue text.

Tags: 

Anticancer Antibody Receives First Funds for Trial in Leukemia Patients

An anti-leukemia compound identified at NCI at Frederick is one step closer to entering clinical trials in humans thanks to a $4.2-million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). CPRIT recently gave the funds to Allterum Therapeutics, Inc., a Texas-based biotechnology startup company created to manufacture the compound, Allterum, and advance it to human trials. The grant represents the first step in the multi-million-dollar process to bring Allterum to the clinic.

Tags: 

Pages

Subscribe to Science